As new information is available, AAFP’s page will be updated to help members effectively prepare practices, counsel patients and administer the vaccine.
To date, no COVID-19 vaccine candidates have been approved by the FDA. All of the candidates are going through clinical trials, with only a few options moving into phase III trials. Currently there is not a vaccine approved or authorized by the FDA; worldwide, there are 46 vaccine candidates in phase 1-3 trials. Four vaccine candidates are in phase III trials for potential use in the U.S: two candidates are using viral vectors as a vehicle for the SARS-CoV-2 proteins while the other two candidates candidates are using SARS-CoV-2 mRNA, which have cold-chain requirements. Only one candidate does not require a booster.
View a list of vaccine candidates and phase of development in a World Health Organization report.
The CDC and agencies are working on a distribution plan to roll out the vaccine in the U.S. Initially, there will be limited quantities of the vaccine available so priority will be given for certain populations like front line healthcare workers and those at greatest risk of morbidity and mortality from COVID-19.
As the amount of vaccine and supplies ramp up, the vaccine will be distributed more broadly. AAFP and other organizations are actively providing input into this process and advocating strongly for equitable distribution.
AAFP Vaccine Resources
The AAFP and other primary care organizations work with the CDC’s Advisory Committee on Immunization Practices to develop recommendations for the routine use of immunizations. This work is aided through AAFP members serving on the committee as well as its work group. The immunization schedules are reviewed and approved by the AAFP each year.
Similarly, any recommendations for a COVID-19 vaccine will receive input from family physicians and will be reviewed by the AAFP. The AAFP has issued several statements calling for a transparent review and approval process that adheres to a scientifically rigorous standards to ensure safety and effectiveness of the vaccine.